Ebola trials begin as fresh cases confirmed
The mid-stage, or Phase II, trials are designed primarily to test the vaccines’ safety, but will also assess whether they provoke an immune response against the deadly virus.
The development of the prime-boost and other vaccines was accelerated in response to vast outbreaks of ebola in West Africa, where at least 11,200 people have died so far in Guinea, Sierra Leone and Liberia.
